CLINICAL_TRIALS
trial_result
· 2009-12-24
Clinical Trial Update: ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) [Phase 2]
Summary
A Phase 2 study evaluating ADX10059 as monotherapy for gastroesophageal reflux disease has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Addex Pharma S.A. | Conditions: Gastroesophageal Reflux | Phase 2 | Status: COMPLETED